Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

OTLK
Outlook Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
Jul 29, 2026 12:00:29 PM EDT
0.9700USD+7.580%(+0.0700)21,325,493
0.9600Bid   1.11Ask   0.1500Spread
Pre-market
Jul 29, 2026 9:23:30 AM EDT
0.8810USD-1.795%(-0.0160)69,786
After-hours
Jul 28, 2026 4:56:30 PM EDT
0.8955USD-0.178%(-0.0016)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:18AM EST  Outlook Therapeutics Provides A Corporate Update And Business Outlook   Benzinga
Jan 19, 2022
08:05AM EST  Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in theVirtual Investor 2022 Top Picks Conferenceon Tuesday, January 25, 2022 at 3:00 PM ET.   GlobeNewswire Inc
Jan 4, 2022
08:35AM EST  Outlook Therapeutics to Present at the H.C. Wainwright BioConnect   GlobeNewswire Inc
Dec 22, 2021
09:12AM EST  Recap: Outlook Therapeutics Q4 Earnings   Benzinga
08:10AM EST  Outlook Therapeutics FY21 EPS $(0.35) Up From $(0.67) YoY   Benzinga
08:05AM EST  Outlook Therapeutics Reports Financial Results for Fiscal Year   GlobeNewswire Inc
Dec 15, 2021
08:05AM EST  Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial   GlobeNewswire Inc
Dec 10, 2021
07:50AM EST  The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares   Benzinga
Dec 9, 2021
08:05AM EST  Outlook Therapeutics to Present at the 14th Asia-Pacific   GlobeNewswire Inc
Dec 2, 2021
06:18AM EST  Outlook Therapeutics Director GMS Ventures & Investments Reported Purchase of 16,000,000 Shares @ Avg Price of $1.25/Share in Form 4 Filing on Wednesday   Benzinga
Nov 29, 2021
04:15PM EST  Outlook Therapeutics Announces Closing of $57.5 Million Bought   GlobeNewswire Inc
Nov 24, 2021
07:32AM EST  The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension   Benzinga
Nov 23, 2021
10:30PM EST  Outlook Therapeutics Increases Previously Announced Bought Deal   GlobeNewswire Inc
04:31PM EST  Outlook Therapeutics Announces $10M Bought Deal Offering Of Common Stock   Benzinga
04:30PM EST  Outlook Therapeutics Announces $10 Million Bought Deal Offering of   GlobeNewswire Inc
Nov 13, 2021
11:00AM EST  - NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data   GlobeNewswire Inc
Nov 10, 2021
08:05AM EST  Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that members of management will participate in theVirtual Investor Roundtable Eventon Tuesday, November 16, 2021 at 9:00 AM ET.   GlobeNewswire Inc
Nov 9, 2021
11:54AM EST  Outlook Therapeutics Sponsored Study Titled 'A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NORSE SEVEN)' Posted To ClinicalTrials.gov; Study Not Recruiting   Benzinga
Nov 4, 2021
08:05AM EDT  Outlook Therapeutics to Present at the Retina Subspecialty Day,   GlobeNewswire Inc
Nov 3, 2021
08:05AM EDT  Outlook Therapeutics to Present at the Eyecelerator@AAO 2021   GlobeNewswire Inc
Oct 12, 2021
12:00PM EDT  Outlook Therapeutics Positive NORSE THREE Safety   GlobeNewswire Inc
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 7, 2021
08:09AM EDT  Outlook Therapeutics To Present At The 2021 American Society Of Retina Specialists Annual Meeting   Benzinga
08:05AM EDT  Outlook Therapeutics to Present at the 2021 American Society of   GlobeNewswire Inc
Oct 5, 2021
08:44AM EDT  Outlook Therapeutics To Present At Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase Oct. 7   Benzinga
08:05AM EDT  Outlook Therapeutics to Present at the Ophthalmology Innovation   GlobeNewswire Inc
Sep 28, 2021
08:45AM EDT  Outlook Therapeutics Inc. (OTLK) said new 12-month safety data from the pivotal Phase 3 NORSE TWO trial that further confirmed the strong safety profile in the study of ONS-5010 / LYTENAVA (bevacizumab-vikg) for treatment of neovascular age-related macular degeneration or wet AMD.   RTTNews
08:13AM EDT  Outlook Therapeutics Reports New Positive 12-Month Safety Data From Pivotal Phase 3 NORSE TWO Trial   RTTNews
08:06AM EDT  Outlook Therapeutics Reports 12-Month Safety Data From Pivotal Phase 3 NORSE TWO Trial: 'Full year data reinforce strong safety profile consistent with previous trials...'   Benzinga
08:05AM EDT  -- Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab -- Full data to be presented at American Academy of Ophthalmologys Retina Subspecialty Meeting, RET13 - Section X: Late Breaking Developments, Part II on November 13th at 9:17 AM ET   GlobeNewswire Inc
Sep 21, 2021
08:05AM EDT  Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual   GlobeNewswire Inc
Sep 13, 2021
08:26AM EDT  Outlook Therapeutics Presents Positive NORSE THREE Safety Data For ONS-5010/LYTENAVA At EURETINA 2021 Medical Conference   RTTNews
08:12AM EDT  Outlook Therapeutics Highlights Presentation Of NORSE THREE Safety Data For ONS-5010 / LYTENAVA At EURETINA Virtual 2021 Medical Conference   Benzinga
08:05AM EDT  Outlook Therapeutics Presents Positive NORSE THREE Safety Data   GlobeNewswire Inc
Sep 8, 2021
08:05AM EDT  Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual   GlobeNewswire Inc
Aug 13, 2021
09:41AM EDT  Outlook Therapeutics: Q3 Earnings Insights   Benzinga
08:09AM EDT  Outlook Therapeutics Q3 EPS $(0.07) Down From $(0.03) YoY   Benzinga
08:05AM EDT  -- Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD)   GlobeNewswire Inc
Aug 11, 2021
08:05AM EDT  -- Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17th at 9:00 AM ET   GlobeNewswire Inc
Aug 3, 2021
12:35PM EDT  Mid-Morning Market Update: Markets Down; Alibaba Posts Downbeat Q1 Sales   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
06:09AM EDT  Outlook Therapeutics Reports Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA For Treatment Of Wet AMD Achieved Statistically Significant Primary And Key Secondary Efficacy Endpoints   Benzinga
06:00AM EDT  -- In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15 letters -- In NORSE TWO, ONS-5010 was safe and well tolerated -- Management to host conference call and webcast today at 8:00 a.m. ET   GlobeNewswire Inc
Jul 29, 2021
10:37AM EDT  Outlook Therapeutics Files For U.S. Patent Titled 'BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES'   Benzinga
Jul 7, 2021
08:08AM EDT  Outlook Therapeutics Appoints C. Russell Trenary III As President And Chief Executive Officer   Benzinga
08:05AM EDT  -- Experienced executive with a track-record of successful eye care product launches -- Appointment reflects Outlook Therapeutics dedication to transition to commercial-stage company   GlobeNewswire Inc
Jun 14, 2021
08:07AM EDT  Outlook Therapeutics to Join the Russell 2000 Index   Benzinga
08:05AM EDT  Outlook Therapeutics Announces Inclusion in the Russell   GlobeNewswire Inc
Jun 8, 2021
08:12AM EDT  Outlook Therapeutics Reports Completion Of Patient Dosing In The ONS-5010 Pivotal Phase 3 NORSE TWO Trial   Benzinga
08:05AM EDT  -- Topline readout of data from NORSE TWO targeted for calendar Q3 2021 -- New Biologics License Application (BLA) filing anticipated in calendar Q1 2022   GlobeNewswire Inc
May 27, 2021
08:07AM EDT  Outlook Therapeutics Highlights May 20 Virtual Clinical Day   Benzinga
08:05AM EDT  -- Drs.Mark Humayun and Firas Rahhal, leading retinal specialists and Advisors to Outlook Therapeutics, stress clinical value of ONS-5010, if approved, over existing treatment options -- Registration clinical program and pre-commercialization planning for ONS-5010 remains ongoing with key catalysts expected over the next year -- Webcast replay is now available:click here   GlobeNewswire Inc
May 14, 2021
08:14AM EDT  Outlook Therapeutics Q2 Net Loss Attributable $13.1 Mln Or $0.09/Shr Vs Loss $17.5 Mln Or $0.36/Shr Year-ago   RTTNews
08:10AM EDT  Outlook Therapeutics Q2 EPS $(0.09) Up From $(0.13) YoY   Benzinga
08:05AM EDT  -- Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021 -- Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience trial (NORSE ONE)   GlobeNewswire Inc
May 12, 2021
08:05AM EDT  Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021   GlobeNewswire Inc
Mar 31, 2021
09:23AM EDT  Outlook Therapeutics' Bevacizumab-vikg Shows Favorable Safety Profile In Retinal Disease Study   Benzinga
08:29AM EDT  Outlook Therapeutics Reports Positive Safety Profile From NORSE THREE Open-Label Safety Study For ONS-5010 / LYTENAVA   RTTNews
08:11AM EDT  Outlook Therapeutics Reports Safety Profile From NORSE THREE Open-Label Safety Study For ONS-5010 / LYTENAVA; 10% Of PAtients Experienced Adverse Event   Benzinga
08:05AM EDT  -- Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD -- Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021, followed by BLA submission by end of 2021   GlobeNewswire Inc
Mar 4, 2021
09:00AM EST  Outlook Therapeutics to Present at the H.C. Wainwright Global Life   GlobeNewswire Inc
Feb 17, 2021
08:05AM EST  Outlook Therapeutics to Participate in Cantor   GlobeNewswire Inc
Feb 16, 2021
08:09AM EST  Outlook Therapeutics Q1 EPS $(0.12) Up From $(0.62) YoY   Benzinga
08:05AM EST  -- Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021 -- Topline data from the open-label safety study (NORSE THREE) on target to report in Q2 2021 -- Recent funding significantly enhances financial position, extends cash runway through BLA filing and provides strategic optionality to maximize stockholder value   GlobeNewswire Inc
Feb 11, 2021
08:05AM EST  Outlook Therapeutics Reports Final Visit for Last Patient in   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 6, 2021
01:27PM EST  Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More   Benzinga
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
11:18AM EST  Outlook Therapeutics Raises $35M Via Equity To Support ONS-5010 US Application, Shares Spike   Benzinga
09:05AM EST  Overallotment option on recent public offering partially exercised by underwriter   GlobeNewswire Inc
Feb 3, 2021
05:33AM EST  Outlook Therapeutics Director GMS Ventures & Investments Reported Purchase of 8,360,000 @ Recent Offering Price of $1.00/Share in Form 4 Filing on Tuesday   Benzinga
Feb 2, 2021
04:05PM EST  Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal   GlobeNewswire Inc
Jan 29, 2021
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
12:39AM EST  Outlook Therapeutics Increase Size Of Public Offering And Purchase On Firm Commitment Basis 35 Mln Shares At $1/Shr   RTTNews
Jan 28, 2021
05:24PM EST  Outlook Therapeutics Reports $10M Bought-Deal Offering Of Common Stock   Benzinga
Jan 12, 2021
08:05AM EST  Leading Ophthalmology Organization Launches Podcast Video with   GlobeNewswire Inc
Jan 5, 2021
08:00AM EST  Outlook Therapeutics to Present at the H.C. Wainwright BioConnect   GlobeNewswire Inc
Dec 23, 2020
09:43AM EST  Outlook Therapeutics shares were trading higher after the company reported FY20 EPS results up from last year.   Benzinga
09:13AM EST  Outlook Therapeutics FY20 EPS $(0.67) Up From $(1.98) YoY   Benzinga
09:05AM EST  -- All planned clinical trials for ONS-5010 / LYTENAVA (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed -- Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021   GlobeNewswire Inc
Dec 1, 2020
08:09AM EST  Outlook Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement   Benzinga
08:05AM EST  Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid   GlobeNewswire Inc
Nov 19, 2020
08:05AM EST  -- Advisory Council to collaborate on outreach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevacizumab   GlobeNewswire Inc
Nov 11, 2020
09:05AM EST  -- Dr. Rahhal, a leading retinal clinician,offeredinsight on wet AMD treatment and the potential of ONS-5010/LYTENAVA (bevacizumab-vikg), if approved, to improve available treatment options -- Outlook Therapeutics detailedongoing development and pre-commercial planning of ONS-5010/LYTENANA -- Webcast replay from the event is now available: click here   GlobeNewswire Inc
Nov 5, 2020
08:13AM EST  Outlook Therapeutics Secures $10M In Additional Working Capital Through Issuance Of Promissory Note To Accredited Investor   Benzinga
Nov 3, 2020
08:35AM EST  Outlook Therapeutics Reports Completion Of Patient Enrollment Of Open-Label Study For ONS-5010/LYTENAVA   Benzinga
08:35AM EST  -- Full enrollment of 195subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule -- All planned clinical trials for ONS-5010/LYTENAVA BLA for wet AMD now fully enrolled or completed -- Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021   GlobeNewswire Inc
Oct 22, 2020
08:00AM EDT  Outlook Therapeutics, Inc. (Nasdaq: OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikgfor use in retinalindications, today announced that members of management will participate in the Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 10:00 AM ET.   GlobeNewswire Inc
Oct 13, 2020
08:06AM EDT  Outlook Therapeutics Reports Initiation Of Supplemental Open-Label Safety Study For ONS-5010/LYTENAVA; First Subjects Have Been Enrolled   Benzinga
08:05AM EDT  Outlook Therapeutics Announces Initiation of Supplemental   GlobeNewswire Inc
Oct 7, 2020
08:05AM EDT  Outlook Therapeutics, Inc. (Nasdaq: OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikgfor use in retinalindications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate at the BIO Investor Forum Digital taking place on October 13-15, 2020.   GlobeNewswire Inc
Sep 30, 2020
08:09AM EDT  Outlook Therapeutics Highlights Progress On ONS-5010 Program   Benzinga
08:05AM EDT  Outlook Therapeutics Provides Update on Progress Towards First   GlobeNewswire Inc
Sep 8, 2020
08:05AM EDT  Outlook Therapeutics, Inc. (Nasdaq: OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikgfor use in retinalindications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at two upcoming investor conferences in September.   GlobeNewswire Inc
Aug 27, 2020
06:09AM EDT  HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Lowers Price Target to $5   Benzinga
Aug 26, 2020
08:12AM EDT  Outlook Therapeutics Reports Topline Results And Proof-of-Concept For ONS-5010 / LYTENAVA From NORSE 1   Benzinga
08:12AM EDT  Outlook Therapeutics Reports Topline Results And Positive Proof-of-Concept For ONS-5010 / LYTENAVA From NORSE 1   RTTNews
08:05AM EDT  -- ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research -- NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing pivotal NORSE 2 registration trial   GlobeNewswire Inc
Aug 18, 2020
08:02AM EDT  Oppenheimer Maintains Outperform on Outlook Therapeutics, Lowers Price Target to $8   Benzinga
Aug 14, 2020
08:11AM EDT  Outlook Therapeutics Q3 Adj. EPS $(0.11) Up From $(0.24) YoY   Benzinga
08:05AM EDT  -- Successfully completed NORSE 2 enrollment in July 2020 -- NORSE 1 topline results to be reported in August 2020   GlobeNewswire Inc
Jul 17, 2020
08:05AM EDT  Outlook Therapeutics Announces Closing of $1.0 Million Private   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC